Taysha Gene Therapies, Inc. (TSHA)
NASDAQ: TSHA · Real-Time Price · USD
1.430
-0.100 (-6.54%)
Nov 4, 2024, 12:59 PM EST - Market open

Taysha Gene Therapies Ratios and Metrics

Millions USD. Fiscal year is Jan - Dec.
Fiscal Year
CurrentFY 2023 FY 2022 FY 2021 FY 2020 FY 2019
Period Ending
Nov '24 Dec '23 Dec '22 Dec '21 Dec '20 Dec '19
Market Capitalization
2953311414481,002-
Market Cap Growth
963.34%134.50%-68.52%-55.28%--
Enterprise Value
199227170314724-
Last Close Price
1.531.772.2611.6526.54-
PE Ratio
--1.84-0.60-2.51-7.81-
PS Ratio
23.8021.4256.40---
PB Ratio
2.834.42148.704.703.99-
P/FCF Ratio
-5.96-4.30-1.29-3.39-32.53-
P/OCF Ratio
-5.99-4.53-1.60-3.83-32.61-
EV/Sales Ratio
15.4714.6767.98---
EV/EBITDA Ratio
-5.13-3.24-1.36-1.82-16.83-
EV/EBIT Ratio
-5.04-3.18-1.35-1.81-16.83-
EV/FCF Ratio
-5.13-2.95-1.56-2.37-23.48-
Debt / Equity Ratio
0.540.8363.150.66--
Debt / FCF Ratio
-0.77-0.80-0.55-0.48--
Asset Turnover
0.090.100.01---
Quick Ratio
5.053.921.402.8835.24-
Current Ratio
5.224.081.543.0836.170.10
Return on Equity (ROE)
-318.69%-294.04%-344.67%-100.68%-47.79%-
Return on Assets (ROA)
-34.17%-29.84%-46.30%-45.81%-20.76%-
Return on Capital (ROIC)
-50.56%-45.13%-71.82%-52.85%-21.40%-
Earnings Yield
-36.46%-33.71%-117.64%-38.94%-5.99%-
FCF Yield
-24.15%-23.23%-77.25%-29.53%-3.07%-
Buyback Yield / Dilution
-256.03%-164.20%-16.74%-113.13%-83.53%-
Total Shareholder Return
-256.03%-164.20%-16.74%-113.13%-83.53%-
Source: S&P Capital IQ. Standard template. Financial Sources.